Robert Wasinger, senior vice president on McGuireWoods Consulting’s federal public affairs team, was quoted in a Sept. 17 cover story by CQ Magazine.
Was Policy Fellow for House Oversight and Government Reform Committee
Greg Walden, partner at McGuireWoods and senior advisor with McGuireWoods Consulting, recently discussed legal concerns, ethical considerations and policy around autonomous vehicles with the Corporate Counsel Business Journal.
In a Sept. 10 opinion piece for The Hill, McGuireWoods Consulting executive vice president and director, Frank Donatelli, compares the upcoming midterm elections and modern politics to a heavyweight fight.
Former Educator Touts Strong Legislative Affairs Background
Bill of the Week: Tax Cuts 2.0
Well…it’s not going to be an actual bill: Ways and Means Chairman Kevin Brady (R-TX) will release an outline for Tax Cuts 2.0 before the House departs for August recess this week. House GOP tax writers are meeting one more time before the rollout.
This Week: More rules to OMB…House overhauls OTC drug rules…HELP Committee looks at drug costs…FDA outlines reorganization
Your weekly North Carolina political news report.
Final day for early voting - what you should know
Word of the Week: Bureaucracy
The OMB and Treasury issued a memorandum of agreement (MOA) in April that established a new interagency process for reviewing certain tax regulations, namely those stemming from the 2017 GOP tax law. And things are working as expected…
The House began its two-week vote-a-thon on opioid legislation. On June 12, 2018 the House passed 25 bills and continued to work on opioid legislation throughout the week. On June 12 all but two of the bills were decided by voice vote, and the debate period for the bills rarely exceeded 10 minutes.
An overview of the upcoming week in Congress from the McGuireWoods Consulting Tax Policy Update Team.
GA-18-380: This report examines the progress the progress the Veterans Health Administration (VHA) has made improving opioid safety through its Opioid Safety Initiative (OSI).
This month, President Trump announced his plan to lower drug prices. The plan does not call for a major overhaul of drug companies’ pricing practices, but does include some proposals that they oppose. Much of Trump’s plan is in the form of suggested actions, and it will take time for actual detailed proposals to be put forward.